Survival in Unresectable Hepatocellular Carcinoma Treated With a New Immune Checkpoint and Antiangiogenic Drug Combination

被引：0
|
作者：
Mezzacappa, Catherine [1 ]
机构：
[1] Yale Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [31] Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
    Guiard, E.
    Baldini, C.
    Pobel, C.
    Martin-Romano, P.
    Champiat, S.
    Hollebecque, A.
    Postel-Vinay, S.
    Varga, A.
    Bahleda, R.
    Gazzah, A.
    Verlingue, L.
    Geraud, A.
    Ningarhari, M.
    Angevin, E.
    Michot, J-M.
    Ribrag, V.
    Marabelle, A.
    Soria, J-C.
    Massard, C.
    Ammari, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1435 - S1435
  • [32] Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
    Guiard, Emeline
    Baldini, Capucine
    Pobel, Cedric
    Assi, Tarek
    Bernard-Tessier, Alice
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Verlingue, Loic
    Geraud, Arthur
    Michot, Jean-Marie
    Armand, Jean-Pierre
    Soria, Jean-Charles
    Massard, Christophe
    Ammari, Samy
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 42 - 53
  • [33] Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
    Xu, Ying
    Wang, Zheng
    Li, Fufeng
    TRANSLATIONAL ONCOLOGY, 2021, 14 (01):
  • [34] MODIFIED ALBI PREDICTED SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH IMMUNOTHERAPY
    Navadurong, Huttakan
    Chaiteerakij, Roongruedee
    Thanapirom, Kessarin
    Komolmitr, Piyawat
    Treeprasertsuk, Sombat
    GASTROENTEROLOGY, 2023, 164 (06) : S1406 - S1407
  • [35] A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
    Guan, Renguo
    Yu, Chengyou
    Li, Shaohua
    Mei, Jie
    Wei, Wei
    Guo, Rongping
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] Development and validation of the SPEAR scoring model and predicting overall survival in unresectable hepatocellular carcinoma patients treated with TACE, molecular targeted therapies, and immune checkpoint inhibitors.
    Li, Wenli
    Lu, Mingjian
    Shi, Feng
    Cheng, Xiao
    Lu, Ruyi
    Fan, Wenzhe
    Zang, Mengya
    Hu, Xiaoyun
    Li, Qi
    Li, Rong
    Zhu, Peilin
    Chen, Yongru
    Su, Kaiyan
    Cai, Qingxian
    Yuan, Guosheng
    Chen, Jinzhang
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 533 - 533
  • [37] Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
    Li, Rong
    Li, Wenli
    Yang, Qing
    Guan, Yujuan
    Chen, Yongru
    Zhu, Peilin
    Su, Kaiyan
    Li, Qi
    Hu, Xiaoyun
    Zang, Mengya
    Zhao, Miaoxian
    Zhong, Manhua
    Yan, Jingquan
    Yang, Keli
    Zhu, Wei
    Lin, Zhanzhou
    Yuan, Guosheng
    Chen, Jinzhang
    LIVER INTERNATIONAL, 2025, 45 (04)
  • [38] Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
    Zhang, Jin-Xing
    Chen, Pei
    Liu, Sheng
    Zu, Qing-Quan
    Shi, Hai-Bin
    Zhou, Chun-Gao
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 265 - 272
  • [39] Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
    Xie, Diyang
    Sun, Qiman
    Wang, Xiaoying
    Zhou, Jian
    Fan, Jia
    Ren, Zhenggang
    Gao, Qiang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (08)
  • [40] Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
    Sun, Liwei
    Xu, Xuelong
    Meng, Fanguang
    Liu, Qian
    Wang, Hankang
    Li, Xiaodong
    Li, Guijie
    Chen, Feng
    FRONTIERS IN ONCOLOGY, 2022, 12
12345